NASDAQ · LUCD

Lucid Diagnostics Inc.

$0.90 -$0.00 (-0.46%) 1D After hours

Key Metrics

$173.14M
Market cap
P/E · TTM
Revenue · TTM
−$45.01M
Net income
EPS · TTM $-0.61
Dividend yield
Free cash flow
Beta · 1Y 1.29
EBITDA · TTM −$44.14M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Feb 26 high, the share price fell 39%.

    Peak close $1.47 on Feb 26; trough close $0.90 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -39%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jul 15
    The stock moved +15.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 15
  • Apr 23
    The stock moved -16.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 23

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$173.14M
Enterprise value
Shares outstanding190.8M
52-wk range$0.90 – $1.63
Avg volume · 20D465.8K
Net cash
Book value / share$0.05
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Lucid Diagnostics Inc.
IPO dateOct 14, 2021
Employees82

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifica…

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC -958.6% · —

Financial Health

Current ratio1.07
Quick ratio1.05
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.98M

Cash Flow · TTM

Operating CF −$46.12M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings